What is Osteoarthritis Pain Drugs Market?
Osteoarthritis is also known as degenerative joint disease or degenerative arthritis is a chronic disease which is characterized by the deterioration of cartilage in the joint which results in stiffness, pain and impaired movement of bones when get rubbed together. The disease most commonly affects the joints in that knee, hands, feet and spine and relatively common in the shoulder and hip joints.
The market study is being classified by Type (Oral, Injection and External), by Application (Medical Care and Personal Care) and major geographies with country level break-up.
Pfizer Inc. (United States), Johnson & Johnson (United States), GlaxoSmithKline (United Kingdom), Mylan (United States), Eli Lilly and Company (United States), Abbott Laboratories (United States), Bioventus, Inc. (United States), Sanofi (France), Flexion Therapeutics, Inc. (United States), Alkem Laboratories (India), Anika Therapeutics, Inc. (United States), Chugai Pharmaceutical Co.( Japan) and Zimmer Biomet Holdings, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Horizon Pharma Plc (Dublin), Ferring B.V.(Switzerland), Bayer (Germany), Almatica Pharma (United States), TEVA (Isreal) and Iroko Pharmaceuticals (United States).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Osteoarthritis Pain Drugs market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Osteoarthritis Pain Drugs market by Type, Application and Region.
On the basis of geography, the market of Osteoarthritis Pain Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rise in Geriatric Population
- Increased Prevalence of Osteoarthritis Across The Globe
- Rich Pipeline Of Innovative Treatment Options
- The Severe Side Effects Of The Drugs
- High Cost Of Advanced Treatments
- Rise in Awareness Regarding Degenerative Bone Diseases In Developing Countries
- Loss Of Patent Exclusivity Of Branded Therapies
According to the United Nations, "By 2050 people aged over 60 will account for more than 20% of the world’s population. Of that 20%, a conservative estimate of 15% will have symptomatic OA, and one-third of these people will be severely disabled. This means that by 2050, 130 million people will suffer from OA worldwide, of whom 40 million will be severely disabled by the disease."
Key Target AudienceOsteoarthritis Pain Drugs Manufacturers and Distributors, Healthcare Institutions (hospitals, medical schools, and outpatient clinics), Market Research and Consulting Firms, Venture Capitalists and Investors and Research & Development Companies